Johns Hopkins All Children’s Cancer and Blood Disorders Institute, St. Petersburg, FL

Hemostasis and Thrombosis Inpatient Service - Attending Lead Physician

The Johns Hopkins All Children’s Cancer and Blood Disorders Institute (CBDI) in St. Petersburg, Florida is pleased to announce the recruitment of a junior faculty member in pediatric hematology to work closely with senior leaders in pediatric coagulation and be integral in the development of a new Hemostasis and Thrombosis (HAT) skill set for outpatient and inpatient service at Johns Hopkins All Children’s Hospital (JHACH). Leadership opportunities may be available based on the experience/training of this individual. The HAT expert faculty position is designed to seamlessly integrate with the outpatient thrombosis, stroke and bleeding disorder clinics. This person will provide ongoing consultative co-management for inpatients with thrombosis, bleeding (hemostasis), stroke, VAD, and ECMO throughout their duration of hospitalization. The individual will be expected to participate in the general hematology inpatient service and outpatient clinics, as well.  The physician will also provide care for stroke, thrombosis and sickle cell patients as part of a team of pediatric benign hematology subspecialists in the outpatient setting. In addition, this individual may pursue mentored research and quality/safety initiatives within HAT and/or benign hematology. Candidate requirements include completion of an ACGME fellowship in pediatric hematology-oncology. Additional fellowship training in HAT is strongly preferred but not required. Depending upon candidate qualifications, either a part-time or full-time faculty appointment is possible in the Division of Hematology, Department of Pediatrics, Johns Hopkins University School of Medicine.

The Comprehensive Hemophilia and Bleeding Disorders Treatment Center at Johns Hopkins All Children’s Hospital is a multidisciplinary federally funded program that provides family-centered, compassionate care to patients with a bleeding disorder. Patients and their families receive comprehensive care and services to address all aspects of life impacted by a bleeding disorder. The JHM Pediatric Thrombosis Program is one of the largest in the country, caring for approximately 100 new patients annually across the Baltimore and St. Petersburg campuses. Both the JHM Pediatric Thrombosis Program and the JHM Pediatric Sickle Cell Program are international leaders in clinical trials in their fields, including active roles as a clinical coordinating center, data coordinating center, and/or central biorepository for multicenter investigator-initiated studies. In addition, the program leads bi-campus cohort and biobanking studies in HAT and serves as a very active center in the International Pediatric Stroke Study.

Colleagues on the team of pediatric benign hematology subspecialists at JHACH include:

  • Irmel Ayala, M.D. Hemostasis; Team Leader for Hematology, Director of 340B Hemophilia program
  • Leila Jerome Clay, M.D., MCTS Director, Comprehensive Sickle Cell Disease Program; Hemoglobinopathy
  • Valerie Cruz-Flores, M.D. Hematologist/Oncologist
  • Neil Goldenberg, M.D., Ph.D. Director of Thrombosis Program; Co-Director of Stroke Program (primary mentor)
  • HAT Service Physician. Benign Heme, Hemostasis, Thrombosis

Baltimore-based JHM colleagues in pediatric hematology include:

  • James Casella, M.D. Division Chief; Director of 340B Hemophilia Program; Director of Pediatric Sickle Cell Program
  • Courtney Lawrence, M.D., Ph.D. Co-Director of Pediatric Anticoagulation Management Service

JHACH is a 259-bed teaching hospital, ranked as a U.S. News & World Report Best Children's Hospital in eight pediatric specialties (2020-2021), including Cancer. Resources include a Clinical and Translational Research Organization, state-of-the-art Biorepository, and multi-omics Molecular Determinants Center and Core. As one of the largest pediatric Hematology-Oncology centers in the southeastern United States, the CBDI is a leading center for treatment and clinical research. Clinical areas of focus for the CBDI include benign hematology, comprehensive sickle cell program, coagulation and thrombophilia, vascular malformations, familial cancer, neuro-oncology, hematologic malignancies, sarcoma, neuroblastoma and bone marrow transplantation. As the Institute continues to grow, collaborative relationships are also expanding with the JHU Department of Oncology, the Sydney Kimmel Cancer Center, the JHU SOM Division of Pediatric Hematology, Moffitt Cancer Center and Tampa General Hospital. These relationships give clinicians and researchers access to clinical trials, translational research opportunities and internationally recognized expertise.

The CBDI has over 130 diverse active therapeutic and supportive care studies that are investigator-initiated, industry-sponsored, or offered through national organizations such as the Children’s Oncology Group and various other consortia. The creation of our pediatric Biorepository and Molecular Determinants Core provide additional opportunities for phase 1, 2, 3 and pilot studies.

The Tampa-St. Petersburg area is a wonderful place to work and live, offering year-round sunshine, abundant cultural and recreational activities, sports venues, excellent schools and an affordable cost of living. Johns Hopkins All Children’s Hospital is centrally located to many of Florida's amenities, only minutes from Tampa and the beautiful gulf beaches, two hours from Orlando, and four hours from Miami.


To confidentially learn more details, please contact Joe Bogan at [email protected], Providence Healthcare Group, (817) 424-1010.